Semaglutide denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Semaglutide as Non-Formulary — and What to Do Next

A non-formulary denial means semaglutide is either not listed on BCBS's drug formulary for your plan, or it sits on a tier that your plan does not cover without a formulary exception. This is an administrative classification, not a clinical judgment — and formulary exception requests succeed regularly when clinical necessity is well-documented.

## Why This Denial Happens

BCBS manages a tiered formulary that changes annually and may vary by plan. Semaglutide's placement on the formulary — or its absence — often reflects cost negotiations rather than clinical appropriateness. When a drug is non-formulary, BCBS typically requires a formulary exception before it will cover the medication, and that exception process runs on the same track as a standard prior-authorization appeal.

## Your Federal Appeal Rights

• Formulary exception request: This is your first step and often resolved without a formal appeal. Your prescriber submits a request explaining why no formulary alternative is clinically appropriate for you.
• Internal appeal: If the exception is denied, file a formal internal appeal within 180 days. Standard decisions within 30–60 days; expedited within 72 hours.
• External review (ACA §2719): After exhausting internal review, request independent external review within approximately 4 months of the final denial. External reviewers assess whether the formulary exclusion, as applied to your clinical facts, results in a medically inappropriate denial.
• ERISA §503: For employer self-funded plans, full-and-fair review and federal court review are available.
• Expedited option: Available when delay poses a serious health risk.

## Documentation to Gather

1. Formulary alternative trial history: BCBS will typically require evidence that formulary alternatives were tried and failed, or a clinical explanation of why they are contraindicated or otherwise inappropriate. List each alternative by name with dates and documented outcomes. 2. Clinical differentiation letter: Your prescriber should explain, in writing, why semaglutide is specifically necessary for your condition when formulary alternatives are inadequate — referencing the FDA-approved prescribing information and the applicable professional guideline organization. 3. Diagnosis and severity documentation: Chart notes confirming the diagnosis and clinical status that make semaglutide the appropriate choice. 4. BCBS formulary and exception criteria: Download the current BCBS formulary for your plan year and the formulary exception criteria. Address each criterion explicitly.

## Criteria-Mapping Structure

For each formulary exception criterion BCBS requires, provide a direct answer from the clinical record:

| BCBS Formulary Exception Criterion | Your Supporting Evidence | |---|---| | [Formulary alternative tried and failed] | [Drug name, dates, documented outcome] | | [Medical necessity for non-formulary agent] | [Prescriber letter referencing FDA label and guidelines] | | [Diagnosis or indication criterion] | [Chart note, ICD-10 code, date confirmed] |

Submit the formulary exception request and the internal appeal together if the exception has already been denied. Attach the current year's formulary showing semaglutide's tier status as Exhibit A, and the prescriber's letter as Exhibit B. Label all exhibits and reference each one in the cover letter.